During a live event, Christine M. Parseghian, MD, examined the key trials guiding treatment selection for a patient who received 2 prior lines of therapy for metastatic colorectal cancer.
Options in Previously Treated Metastatic Colorectal Cancer
John L. Marshall, MD, discusses the challenges faced by oncologists in managing colorectal cancer treatments seen during a Case-Based Roundtable event.
During a live event, Michael J. Overman, MD, discussed biomarker testing, ctDNA, and later-line treatment options for metastatic colorectal cancer.
Marwan G. Fakih, MD, discusses barriers that create treatment differences in metastatic colorectal cancer for community oncologists.
John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal cancer.
Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.
Marwan G. Fakih, MD, discusses topics in metastatic colorectal cancer from the Case-Based Roundtable meeting he moderated.
John L. Marshall, MD, discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer.
John L. Marshall, MD, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.
John L. Marshall, MD, discusses the impact of the SUNLIGHT trial in patients with refractory metastatic colorectal cancer.